Project Grant R01CA280972
- This Project Grant awarded by the National Cancer Institute (NCI), under the federal Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $399,789 to Ergami Endoscopy, Inc. to develop an automated robotic flexible overtube device capable of blind insertion during colonoscopy procedures. The device aims to reduce physician injuries, improve productivity, and decrease patient pain/sedation requirements for the over 16 million colonoscopies performed annually in the U.S. Key...
- The National Cancer Institute (NCI) awarded a $621,406 Project Grant on August 1, 2025, under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353) to Fred Hutchinson Cancer Center to evaluate a multilevel intervention designed to improve follow-up colonoscopy completion rates among patients with abnormal Fecal Immunochemical Tests (FIT) in safety-net healthcare settings. The PROACT (Promoting Follow-up of Abnormal Colorectal Cancer Screening Tests through Multilevel...
- Vigilant Laboratories LLC received a $1,021,347 Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) to develop a commercializable point-of-care (POC) early detection test for oral cavity and oropharyngeal squamous cell carcinoma (OOPSCC). The award, effective September 1, 2025, through August 31, 2027, funds the optimization and advancement of patented biomarker technology combining CD44 (stem cancer cell marker), total...
- Federal Project Grant Award Summary The National Cancer Institute awarded a $297,074 Project Grant to the University of California, Davis on August 8, 2025, under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) to develop and validate Fluorescence Lifetime Imaging (FLIM) technology integrated into standard colonoscopy procedures for enhanced colorectal cancer detection. The research aims to address significant limitations in current colonoscopy techniques that contribute to...
- Summary The Kentucky Department for Public Health (KDPH) received a $1,065,610 cooperative agreement awarded August 30, 2025, through the Centers for Disease Control and Prevention's National Center for Chronic Disease Prevention and Health Promotion under the Organized Approaches to Increase Colorectal Cancer Screening program (CFDA 93.800). The award supports a five-year initiative (through August 29, 2030) to increase colorectal cancer screening prevalence in partnered health systems...
- The National Science Foundation awarded $256,000 to Optave Diagnostics LLC through the Technology, Innovation, and Partnerships program (CFDA 47.084) to develop a prototype endoscopic probe for molecular imaging and diagnosis of cancerous prostate pathologies. The 12-month project grant will support the creation of a medical device using photoacoustic imaging and acoustic lens technology to aid in the detection and diagnosis of prostate cancer. The proposed endoscopic probe offers an alternative...
- Federal Cooperative Agreement Summary The Beckman Research Institute of the City of Hope received a $738,675 Cooperative Agreement award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research Program (CFDA 93.394), effective March 16, 2026, through February 28, 2031. The award supports the development and validation of an innovative exosome-based liquid biopsy assay designed for non-invasive early detection of colorectal adenomas and cancers. The deliverable...
- Summary The Alabama Department of Public Health's Cancer Prevention and Control Division received a $483,280 Cooperative Agreement from the Centers for Disease Control and Prevention's National Center for Chronic Disease Prevention and Health Promotion under the Organized Approaches to Increase Colorectal Cancer Screening program (CFDA 93.800) on August 30, 2025, with a completion date of August 29, 2030. The Alabama Colorectal Cancer Program (ACRCP) will implement evidence-based interventions...
- Grant Award Summary The University of Arkansas for Medical Sciences (UAMS) received a $1.63M cooperative agreement from the Centers for Disease Control and Prevention's National Center for Chronic Disease Prevention and Health Promotion under the Organized Approaches to Increase Colorectal Cancer Screening program (CFDA 93.800). The award, effective August 30, 2025, through August 29, 2030, funds the PROTECT-AR initiative to improve colorectal cancer screening rates and health outcomes across...
- Summary Penn State University's Milton S. Hershey Medical Center received a $682,392 cooperative agreement award effective August 30, 2025, through August 29, 2030, from the Centers for Disease Control and Prevention's National Center for Chronic Disease Prevention and Health Promotion under the Organized Approaches to Increase Colorectal Cancer Screening program (CFDA 93.800). The Pennsylvania Colorectal Cancer Alliance to Reduce Mortality and Enhance Screening (PA-CARES) initiative will...
COLORECTAL CANCER SCREENING WITH OPTICAL COHERENCE TOMOGRAPHY - THE OVERALL INCIDENCE RATE OF COLORECTAL CANCER (CRC) HAS DECLINED OVER THE PAST TWO DECADES LARGELY DUE TO POPULATION-BASED COLONOSCOPIC SCREENING FOR AND REMOVAL OF PRECURSOR ADENOMAS. EVEN THOUGH COLONOSCOPY HAS BEEN BENEFICIAL FOR CANCER INTERCEPTION, IT HAS LIMITATIONS THAT HAVE SUBSTANTIAL FINANCIAL AND HEALTH CONSEQUENCES. NEARLY ALL COLONOSCOPY PATIENTS IN THE US UNDERGO CONSCIOUS SEDATION/ANESTHESIA WHICH IS RESPONSIBLE FOR ~$15B IN HEALTH CARE COSTS ANNUALLY. RESECTION OF POLYPS, MANY OF WHICH DO NOT HAVE NEOPLASTIC POTENTIAL, IS ALSO EXPENSIVE, RAISING COLONOSCOPY COSTS BY ~50%. COLONOSCOPY MISSES MANY ADENOMAS, LEADING TO A HIGH RATE OF INTERVAL CANCERS, ACCOUNTING FOR ABOUT 7,000 NEW CRC CASES EACH YEAR. KEY FACTORS LEADING TO THIS HIGH MISS RATE INCLUDE THE FORWARD-VIEWING ENDOSCOPE THAT MISSES POLYPS BEHIND COLONIC FOLDS, SUBTLE SERRATED PRECURSOR LESIONS, AND DISPARITIES IN ENDOSCOPIST PROFICIENCY. THESE ISSUES UNDERLIE UNMET NEEDS FOR IMPROVED ADENOMA SCREENING TECHNOLOGIES THAT 1) ENABLE THE ENTIRE COLON TO BE VISUALIZED, INCLUDING BEHIND MUCOSAL FOLDS, 2) ARE MORE SENSITIVE AND OBJECTIVE FOR POLYP IDENTIFICATION, 3) PROVIDE REAL-TIME POLYP DIAGNOSIS, AND 4) CAN DETECT AND TREAT ADENOMAS BY AT THE POINT OF CARE WITHOUT REQUIRING SEDATION. OPTICAL COHERENCE TOMOGRAPHY (OCT) IS A CROSS-SECTIONAL IN VIVO MICROSCOPY IMAGING TECHNOLOGY THAT WITH FURTHER DEVELOPMENT CAN ADDRESS MANY OF THESE ADENOMA SCREENING NEEDS. HERE, WE WILL CREATE AND CLINICALLY VALIDATE A NEW OCT SYSTEM AND TWO DISTINCT OCT PROBES THAT ARE OPTIMIZED FOR ADENOMA SCREENING. THE OCT SYSTEM WILL UTILIZE INNOVATIVE TECHNOLOGY TO OBTAIN THREE-DIMENSIONAL MICROSCOPIC IMAGES OF THE ENTIRE COLON IN 5 MINUTES (AIM 1.3). ONE OF THE PROPOSED OCT IMAGING PROBES WILL OPERATE THROUGH THE ACCESSORY PORT OF A COLONOSCOPE, ACCELERATING CLINICAL TRANSLATION THROUGH ITS COMPATIBILITY WITH STANDARD OF CARE COLONOSCOPY (AIM 1.1). THIS PROBE WILL UTILIZE NOVEL EXTENDED DEPTH OF FOCUS (EDOF) OPTICS, ALLOWING IT TO BE CENTERED IN THE COLON'S LUMEN AND CAPTURE HIGH-RESOLUTION, CROSS-SECTIONAL OCT IMAGES THAT RETAIN 3D TOPOLOGY. WE WILL USE THIS COLONOSCOPE- COMPATIBLE PROBE IN A CLINICAL STUDY OF 200 PATIENTS TO DEVELOP AND TEST AN AUTOMATED MACHINE LEARNING ALGORITHM FOR POLYP CLASSIFICATION IN VIVO (AIM 2). THE SECOND OCT PROBE, TERMED A RETROGRADE TETHERED CAPSULE ENDOMICROSCOPE (R-TCE), WILL BE DESIGNED TO SCREEN FOR ADENOMAS IN UNSEDATED PATIENTS AT THE POINT OF CARE (AIM 1.2). THE R-TCE DEVICE WILL BE A TETHERED EDOF OCT IMAGING CAPSULE THAT IS INSERTED INTO THE ANUS AND ADVANCED TO THE CECUM VIA A ROTATING SCREW-LIKE MOTION. ONCE THERE, THE CAPSULE WILL BE CENTERED IN THE LUMEN BY A BALLOON AND PULLED BACK THROUGH THE COLON WHILE IMAGING. AFTER THE CAPSULE IS DEVELOPED, WE WILL CONDUCT A CLINICAL STUDY TO ESTABLISH THE R-TCE CLINICAL PROCEDURE AND THEN TEST SAFETY AND FEASIBILITY OF WHOLE-COLON R-TCE IMAGING IN 45 PATIENTS (AIM 3). FINALLY, TO ENABLE FUTURE TREATMENT OF SMALL ADENOMAS IDENTIFIED BY R-TCE, AN R-TCE DEVICE THAT ABLATES DIMINUTIVE ADENOMAS WILL BE DEVELOPED/TESTED IN A SWINE POLYPOSIS MODEL (AIM 1.4).
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $771.5k | 8/6/25 | ||
| Not listed | ($50k) | 8/6/24 | ||
| Not listed | $760.9k | 7/22/24 | ||
| Not listed | $760.9k | 7/22/24 |